Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer
NCT06141265Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Nov 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Peking University Cancer Hospital & Institute. Started Nov 2023; status: recruiting.
02
Drugs
niraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT06141265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141265.